GO TO NEWSROOMeast
larimar_final logo.pdf.jpg
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
May 29, 2020 08:00 ET | Larimar Therapeutics, Inc.
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020- Company signed $80 million in private placement financing with biotechnology focused...
logo.jpg
Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time
May 29, 2020 08:00 ET | Sanofi
Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time *Across all groups combined, complete...
logo.jpg
Les résultats à long terme de Libtayo® (cemiplimab-rwlc) dans le traitement du carcinome épidermoïde cutané présentés à l’ASCO 2020 montrent des réponses durables et plus prononcées au fil du temps
May 29, 2020 08:00 ET | Sanofi
Les résultats à long terme de Libtayo® (cemiplimab-rwlc) dans le traitement du carcinome épidermoïde cutané présentés à l’ASCO 2020 montrent des réponses durables et plus prononcées au fil du temps ...
Ziopharm_RGB_hires (1).jpg
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology
May 29, 2020 08:00 ET | ZIOPHARM Oncology Inc
 – Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile –   – Controlled IL-12 in combination with PD-1...
athenex-logo_750xx739-416-0-70.jpg
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program
May 29, 2020 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., May 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for...
logo_tagline_NOVAGOLD_web800.jpg
NOVAGOLD Responds to Inaccurate Report from Short-Selling Firm
May 29, 2020 08:00 ET | NOVAGOLD RESOURCES INC.
VANCOUVER, British Columbia, May 29, 2020 (GLOBE NEWSWIRE) -- NOVAGOLD RESOURCES INC. (“NOVAGOLD” or “the Company”) (NYSE American, TSX: NG) responds to a misleading report issued on May 28, 2020 by...
Kura Oncology Logo
Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma
May 29, 2020 08:00 ET | Kura Oncology, Inc.
– Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC – – Outcomes with approved therapies are poor, with reported median OS of 5-8...
VIR_logo_large.jpg
Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
May 29, 2020 08:00 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc....
HCM Hutchison China MediTech tall 129x150.png
Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20
May 29, 2020 08:00 ET | Hutchison China MediTech Limited
― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ―...
kalytera_therapeutics_logo.jpg
Kalytera Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease
May 29, 2020 08:00 ET | Kalytera Therapeutics Inc.
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data demonstrating...